Back to Search Start Over

Discovery of pan-IAP degraders via a CRBN recruiting mechanism.

Authors :
Park S
Kim D
Lee W
Cho JH
Kim S
Lee GS
Moon JH
Kim JA
Ha JD
Kim JH
Kim HJ
Source :
European journal of medicinal chemistry [Eur J Med Chem] 2023 Jan 05; Vol. 245 (Pt 2), pp. 114910. Date of Electronic Publication: 2022 Nov 09.
Publication Year :
2023

Abstract

Inhibitors of apoptosis proteins (IAPs), defined by the presence of baculovirus IAP repeat (BIR) protein domain, are critical regulators of cell survival and cell death processes. Cellular IAP 1/2 (cIAP1/2) and X-linked IAPs (XIAPs) regulate the innate immune signaling pathway through their E3 ubiquitin ligase activity. Peptidomimetics or small-molecule IAP antagonists have been developed to treat various diseases, such as cancer, infection, and inflammation. In this study, we synthesized and characterized IAP-cereblon (CRBN) heterodimerizing proteolysis-targeting chimera (PROTAC), which induces the degradation of cIAP1/2 and XIAP but not CRBN. We demonstrated that this PROTAC inhibits tumor necrosis factor alpha (TNFα)-induced innate immune response and cancer cell migration and invasion, leading to apoptotic cell death. Our study is the first to demonstrate that both cIAPs and XIAP are degradable when applied to the PROTAC strategy.<br />Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Hyun Jin Kim reports financial support was provided by Korea Research Institute of Chemical Technology. Jeong-Hoon Kim reports financial support was provided by Korea Research Institute of Bioscience and Biotechnology.<br /> (Copyright © 2022. Published by Elsevier Masson SAS.)

Details

Language :
English
ISSN :
1768-3254
Volume :
245
Issue :
Pt 2
Database :
MEDLINE
Journal :
European journal of medicinal chemistry
Publication Type :
Academic Journal
Accession number :
36410083
Full Text :
https://doi.org/10.1016/j.ejmech.2022.114910